Abstract:Background
Most personalized cancer care strategies involving DNA sequencing are highly reliant on acquiring sufficient fresh or frozen tissue. It has been challenging to comprehensively evaluate the genome of advanced prostate cancer (PCa) because of limited access to metastatic tissue.
Objective
To demonstrate the feasibility of a novel next-generation sequencing (NGS) based platform that can be used with archival formalin-fixed paraffin-embedded (FFPE) biopsy tissue to evaluate the spectrum of DNA alterat… Show more
“…The data were subjected to exponential growth-curve analysis constrained to share an initial value and to 2-way ANOVA analysis followed by Bonferroni's multiple comparisons test. Significant differences as compared with the vehicle-treated control group (P < 0.05) were detected only for seviteronel at a dose of 100 mg/kg (days [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28].…”
Section: Methodsmentioning
confidence: 97%
“…In addition to enhanced AR expression, there is considerable evidence to suggest that mutations in the AR that alter its response to pharmacological agents may also be important in CRPC (6,21,23). Specifically, treatment failure in patients progressing while on antiandrogens has been attributed to point mutations in the AR: flutamide, T877A; bicalutamide, W741C; and enzalutamide, F876L (6,21,(24)(25)(26)(27).…”
Section: Cyp17 Inhibitors Directly Bind and Antagonize Ar Activitymentioning
confidence: 99%
“…The most recent studies have attributed such resistance to continued AR overexpression, increased adrenal or intratumoral androgen synthesis, expression of constitutively active AR splice variants (AR-V7), glucocorticoid receptor (GR) expression, and AR mutations (5,(19)(20)(21)(22). AR point mutations are rare in early, untreated prostate tumors but commonly arise in treated CRPC tumors (23). These mutations occur most frequently in the AR ligand-binding domain (LBD) and lead to altered ligand pharmacology, such that antiandrogens function as agonists and drive the outgrowth of cells expressing the gain-of-function resistance mutation.…”
“…The data were subjected to exponential growth-curve analysis constrained to share an initial value and to 2-way ANOVA analysis followed by Bonferroni's multiple comparisons test. Significant differences as compared with the vehicle-treated control group (P < 0.05) were detected only for seviteronel at a dose of 100 mg/kg (days [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28].…”
Section: Methodsmentioning
confidence: 97%
“…In addition to enhanced AR expression, there is considerable evidence to suggest that mutations in the AR that alter its response to pharmacological agents may also be important in CRPC (6,21,23). Specifically, treatment failure in patients progressing while on antiandrogens has been attributed to point mutations in the AR: flutamide, T877A; bicalutamide, W741C; and enzalutamide, F876L (6,21,(24)(25)(26)(27).…”
Section: Cyp17 Inhibitors Directly Bind and Antagonize Ar Activitymentioning
confidence: 99%
“…The most recent studies have attributed such resistance to continued AR overexpression, increased adrenal or intratumoral androgen synthesis, expression of constitutively active AR splice variants (AR-V7), glucocorticoid receptor (GR) expression, and AR mutations (5,(19)(20)(21)(22). AR point mutations are rare in early, untreated prostate tumors but commonly arise in treated CRPC tumors (23). These mutations occur most frequently in the AR ligand-binding domain (LBD) and lead to altered ligand pharmacology, such that antiandrogens function as agonists and drive the outgrowth of cells expressing the gain-of-function resistance mutation.…”
“…Abnormal expression patterns of β-catenin have been observed in 20-71% of prostate cancer samples (51)(52)(53), and high levels of β-catenin are concomitantly associated with increasing Gleason score and castration resistance (53,54). Although recent studies showed that mutations in allophycocyanin and β-catenin can be detected in approximately 10% and 12% of castrationresistant prostate cancer, respectively (55)(56)(57), it seems that Wnt/ β-catenin signaling could play a more common role in prostate cancer than would be predicted by the point mutation rates of these downstream effectors (53,58,59). Alterations in Wnt ligands and their modulators that are secreted from prostate epithelia and the surrounding stroma may serve as the alternative mechanism for activation of Wnt signaling in a subset of human prostate cancer.…”
Carcinomas most often result from the stepwise acquisition of genetic alterations within the epithelial compartment. The surrounding stroma can also play an important role in cancer initiation and progression. Given the rare frequencies of genetic events identified in cancer-associated stroma, it is likely that epigenetic changes in the tumor microenvironment could contribute to its tumor-promoting activity. We use Hmga2 (High-mobility group AThook 2) an epigenetic regulator, to modify prostate stromal cells, and demonstrate that perturbation of the microenvironment by stromal-specific overexpression of this chromatin remodeling protein alone is sufficient to induce dramatic hyperplasia and multifocal prostatic intraepithelial neoplasia lesions from adjacent naïve epithelial cells. Importantly, we find that this effect is predominantly mediated by increased Wnt/β-catenin signaling. Enhancement of Hmga2-induced paracrine signaling by overexpression of androgen receptor in the stroma drives frank murine prostate adenocarcinoma in the adjacent epithelial tissues. Our findings provide compelling evidence for the critical contribution of epigenetic changes in stromal cells to multifocal tumorigenesis.
“…In addition, a high rate of deletion or methylation of either ATM or MCPH1, a proximal regulator that recruits ATM to the sites of DNA DSBs, was reported in breast cancer samples (96%, 121 of 126). In prostate cancer, targeted next-generation sequencing has revealed an 8% incidence of ATM mutations (59). ATM is also one of the most commonly mutated genes in pancreatic cancer (60) or lung adenocarcinoma (61).…”
Section: Somatic Atm Mutations In Cancermentioning
Activation of checkpoint arrest and homologous DNA repair are necessary for maintenance of genomic integrity during DNA replication. Germ-line mutations of the ataxia telangiectasia mutated (ATM) gene result in the well-characterized ataxia telangiectasia syndrome, which manifests with an increased cancer predisposition, including a 20% to 30% lifetime risk of lymphoid, gastric, breast, central nervous system, skin, and other cancers. Somatic ATM mutations or deletions are commonly found in lymphoid malignancies, as well as a variety of solid tumors. Such mutations may result in chemotherapy resistance and adverse prognosis, but may also be exploited by existing or emerging targeted therapies that produce synthetic lethal states.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.